Want real case studies? 10 seconds to sign up
Join the platform
Need Regulatory Help? Try Our Platform
Post your regulatory questions or request quotations from verified pharmaceutical consultants worldwide. Get matched with experts who specialize in your market.
April 4, 2026
Approximately 5 minutes
Medical Device Clinical Studies in the United States
Conducting medical device studies in the U.S. requires a deep understanding of FDA classifications, regulatory pathways (IDE vs. IRB), and operational strategies for successful recruitment and retention.
1. Medical Device Risk Classification
The FDA classifies devices based on risk, which dictates the regulatory pathway and level of control required.
- Class I (Low Risk): General controls are sufficient. Most are exempt from pre-market notification. Examples: Manual surgical instruments, medical gloves.
- Class II (Moderate Risk): Requires special controls. Usually follows the 510(k) pathway to show substantial equivalence to a predicate. Examples: Powered wheelchairs, syringes.
- Class III (High Risk): Requires Pre-Market Approval (PMA) due to significant risk. Examples: Heart valves, pacemakers, life-sustaining implants.
2. Operational Framework: The "Leaky Pipe" Recruitment Model
To determine sample size, researchers use the "leaky pipe" framework to account for attrition throughout the recruitment funnel. If a goal is 200 completed subjects, the starting pool must be significantly larger to account for various drop-off points.
- Public at Large: The initial target population.
- Inclusion/Exclusion Criteria: First major filter based on protocol parameters.
- Consenting & Screening: Participants may fail screening or decline to participate.
- Withdrawal/Drop-out: Participants who leave the study before completion.
Standard Study Size Benchmarks
| Study Type | Typical Subjects | Typical Sites |
|---|---|---|
| Early Feasibility / First-in-Human | 10 – 50 | 2 – 5 |
| Pivotal / Pre-market | 100 – 300+ | 10 – 30+ |
| Post-marketing / Registry | 500 – 1,000+ | Large scale |
3. Case Studies and Specific Examples
Case Study A: Neurology – Early Alzheimer’s Diagnosis
Focus: Using a medical device for earlier detection of Alzheimer’s disease.
Methodology: This study utilized ophthalmic evaluation (eye examinations) as a proxy for neurological health. By evaluating specific markers in the eye, the study aimed to provide a less invasive and earlier diagnosis compared to traditional methods. This highlights the cross-therapeutic application of medical devices where eye health data is used to inform neurological conclusions.
Case Study B: Aesthetics – Diversity and Skin Type Reactivity
Focus: Injectable medical device for the infraorbital hollow area (under the eye) to eliminate aging-related hollowing.
Key Challenges & Requirements:
- Total Enrollment: 153 subjects.
- Diversity Mandate: The FDA required at least 10% of enrollment to consist of individuals with "Upper Fitzpatrick" skin types.
- Scientific Rationale: Skin types IV, V, and VI (darker skin) have different melanin levels and elasticity, which can cause different reactions to injections compared to lighter skin types.
- Regulatory Pivot: After interim analysis data was submitted, the FDA requested the sponsor to further increase the number of individuals in these specific demographic areas to ensure safety and efficacy across all populations before final approval.
Case Study C: Aesthetics – Rapid Enrollment via Site Selection
Focus: Clinical trial for a filler targeting the nasolabial folds (the lines running from the side of the nose to the corners of the mouth).
Operational Details:
- Site Count: 3 U.S.-based research sites.
- Target: Randomize 53 subjects total.
- Projected Timeline: 6-week enrollment period.
- Result: Through aggressive management and meticulous site selection, the study completed enrollment 5 weeks ahead of schedule (in just one week).
- Lesson Learned: High-performing sites with existing patient databases in specific therapeutic areas (like aesthetics) can significantly reduce time-to-market.
4. Advanced Monitoring Strategies
Modern U.S. clinical trials are moving away from 100% on-site monitoring. Key practices now include:
- Remote Monitoring: Utilizing digital platforms to review data without physical site visits.
- Risk-Based Monitoring: Focusing on high-impact data points and site performance metrics rather than 100% source data verification (SDV).
ElendiLabs Regulatory Affairs Team
100+ products successfully registered across global markets. Get unbeatable quotations and expert answers — fast.
Ask Anything
We'll follow up with you personally.
100% response rate • Reply within 7 business days
Related Articles
Approximately 5 minutes
U.S. FDA Office of New Drugs (OND) Organization, Functions, and Key Resources
The FDA’s Office of New Drugs (OND) within CDER reviews new drug and biologic applications, provides regulatory oversight for investigational studies, sets policy for efficient approvals, and maintains key databases such as Drugs@FDA and postmarket requirements, operating through eight review offices with 27 divisions focused on specific therapeutic areas.
Approximately 5 minutes
U.S. FDA Initiatives to Ensure Drug Supply Chain Integrity
The U.S. FDA safeguards the drug supply chain—one of the world’s safest—through the Drug Supply Chain Security Act (DSCSA) for electronic tracing, rapid reporting of illegitimate products, anti-counterfeiting guidance, public education campaigns like BeSafeRx and Know Your Source, and international partnerships to prevent counterfeit, stolen, or harmful drugs from reaching patients.
Approximately 5 minutes
U.S. FDA Drug Development and Approval Process Overview
The U.S. FDA’s Center for Drug Evaluation and Research (CDER) ensures marketed drugs are safe and effective by reviewing sponsor-submitted data in applications such as IND for clinical trials, NDA for new drugs, ANDA for generics, BLA for biologics, and OTC monographs or NDAs for nonprescription products.
Approximately 5 minutes
Harmonized Global Registration of a Class II Hemostatic Valve in Six Key Markets
A US medical device manufacturer successfully registered its Class II hemostatic valve in Australia, Brazil, China, India, Pakistan, and Russia by leveraging existing US, Canadian, and EU approvals and applying a harmonized regulatory strategy with core dossier preparation and efficient project management.
Approximately 5 minutes
Local Testing Support for Generic Radiopharmaceuticals During ANDA Registration in China
A global radiopharmaceutical manufacturer successfully completed mandatory local testing of two generic drugs at the official Chinese laboratory as part of its ANDA registration, overcoming challenges in sample importation, customs clearance, and analytical method transfer.